Kristin Lowland Email Address

Vice President of Information Technology at Olema Oncology

Achaogen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE). Plazomicin is an aminoglycoside designed to overcome clinically relevant aminoglycoside resistance mechanisms. In addition, its research and development pipeline includes two programs that specifically target Pseudomonas aeruginosa or Acinetobacter baumannii infections: a program to discover and develop small molecule inhibitors of LpxC, which is an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and a therapeutic antibody program. Its development plan for plazomicin includes over two Phase III clinical trials.

20+ years of strong IT Biotech/Pharma experience with deep strategic and execution capabilities in both pre and post Commercial environments. Prior to joining Olema, I've held leadership roles of increasing responsibility at key global biotech and pharmaceutical companies including Genentech, Roche, Achaogen, Iovance and Medivation (Pfizer). Held pivotal strategic positions at these organizations to rapidly scale IT to support growth, compliance and build great teams.